BDP1 As a Biomarker in Serous Ovarian Cancer

Overview

Journal Cancer Med

Specialty Oncology

Date 2022 Oct 28

PMID 36305848

Authors

Stephanie Cabarcas-Petroski

Gabriella Olshefsky

Laura Schramm

Affiliations

Soon will be listed here.

Abstract

Background: TFIIIB, an RNA polymerase III specific transcription factor has been found to be deregulated in human cancers with much of the research focused on the TBP, BRF1, and BRF2 subunits. To date, the TFIIIB specific subunit BDP1 has not been investigated in ovarian cancer but has previously been shown to be deregulated in neuroblastoma, breast cancer, and Non-Hodgkins lymphoma.

Results: Using in silico analysis of clinically derived platforms, we report a decreased BDP1 expression as a result of deletion in serous ovarian cancer and a correlation with higher and advanced ovarian stages. Further analysis in the context of TP53 mutations, a major contributor to ovarian tumorigenesis, suggests that high BDP1 expression is unfavorable for overall survival and high BDP1 expression occurs in stages 2, 3 and 4 serous ovarian cancer. Additionally, high BDP1 expression is disadvantageous and unfavorable for progression-free survival. Lastly, BDP1 expression significantly decreased in patients treated with first-line chemotherapy, platin and taxane, at twelve-month relapse-free survival.

Conclusions: Taken together with a ROC analysis, the data suggest BDP1 could be of clinical relevance as a predictive biomarker in serous ovarian cancer. Lastly, this study further demonstrates that both the over- and under expression of BDP1 warrants further investigation and suggests BDP1 may exhibit dual function in the context of tumorigenesis.

Citing Articles

The importance of protein domain mutations in cancer therapy.

Chitluri K, Emerson I Heliyon. 2024; 10(6):e27655.

PMID: 38509890 PMC: 10950675. DOI: 10.1016/j.heliyon.2024.e27655.

MAF1 is a predictive biomarker in HER2 positive breast cancer.

Cabarcas-Petroski S, Olshefsky G, Schramm L PLoS One. 2023; 18(10):e0291549.

PMID: 37801436 PMC: 10558074. DOI: 10.1371/journal.pone.0291549.

BDP1 as a biomarker in serous ovarian cancer.

Cabarcas-Petroski S, Olshefsky G, Schramm L Cancer Med. 2022; 12(5):6401-6418.

PMID: 36305848 PMC: 10028122. DOI: 10.1002/cam4.5388.

References

Borck G, Hog F, Dentici M, Tan P, Sowada N, Medeira A . BRF1 mutations alter RNA polymerase III-dependent transcription and cause neurodevelopmental anomalies. Genome Res. 2015; 25(2):155-66. PMC: 4315290. DOI: 10.1101/gr.176925.114. View

Fang Z, Yi Y, Shi G, Li S, Chen S, Lin Y . Role of Brf1 interaction with ERα, and significance of its overexpression, in human breast cancer. Mol Oncol. 2017; 11(12):1752-1767. PMC: 5709663. DOI: 10.1002/1878-0261.12141. View

Cabarcas-Petroski S, Schramm L . BDP1 Alterations Correlate with Clinical Outcomes in Breast Cancer. Cancers (Basel). 2022; 14(7). PMC: 8996959. DOI: 10.3390/cancers14071658. View

Huang C, Zhang Y, Zhong S . Alcohol Intake and Abnormal Expression of Brf1 in Breast Cancer. Oxid Med Cell Longev. 2019; 2019:4818106. PMC: 6874981. DOI: 10.1155/2019/4818106. View

Cairns C, White R . p53 is a general repressor of RNA polymerase III transcription. EMBO J. 1998; 17(11):3112-23. PMC: 1170650. DOI: 10.1093/emboj/17.11.3112. View

Teichmann M, Wang Z, Roeder R . A stable complex of a novel transcription factor IIB- related factor, human TFIIIB50, and associated proteins mediate selective transcription by RNA polymerase III of genes with upstream promoter elements. Proc Natl Acad Sci U S A. 2000; 97(26):14200-5. PMC: 18895. DOI: 10.1073/pnas.97.26.14200. View

Veras I, Rosen E, Schramm L . Inhibition of RNA polymerase III transcription by BRCA1. J Mol Biol. 2009; 387(3):523-31. DOI: 10.1016/j.jmb.2009.02.008. View

Dickersin K, Mayo-Wilson E . Standards for design and measurement would make clinical research reproducible and usable. Proc Natl Acad Sci U S A. 2018; 115(11):2590-2594. PMC: 5856499. DOI: 10.1073/pnas.1708273114. View

Gomez-Roman N, Grandori C, Eisenman R, White R . Direct activation of RNA polymerase III transcription by c-Myc. Nature. 2003; 421(6920):290-4. DOI: 10.1038/nature01327. View

10.

Gartel A, Ye X, Goufman E, Shianov P, Hay N, Najmabadi F . Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3. Proc Natl Acad Sci U S A. 2001; 98(8):4510-5. PMC: 31865. DOI: 10.1073/pnas.081074898. View

11.

Lu M, Tian H, Yue W, Li L, Li S, Qi L . TFIIB-related factor 2 over expression is a prognosis marker for early-stage non-small cell lung cancer correlated with tumor angiogenesis. PLoS One. 2014; 9(2):e88032. PMC: 3921153. DOI: 10.1371/journal.pone.0088032. View

12.

Fekete J, osz A, Pete I, Nagy G, Vereczkey I, Gyorffy B . Predictive biomarkers of platinum and taxane resistance using the transcriptomic data of 1816 ovarian cancer patients. Gynecol Oncol. 2020; 156(3):654-661. DOI: 10.1016/j.ygyno.2020.01.006. View

13.

Sriskanthadevan-Pirahas S, Deshpande R, Lee B, Grewal S . Ras/ERK-signalling promotes tRNA synthesis and growth via the RNA polymerase III repressor Maf1 in Drosophila. PLoS Genet. 2018; 14(2):e1007202. PMC: 5814106. DOI: 10.1371/journal.pgen.1007202. View

14.

Cabarcas S, Watabe K, Schramm L . Inhibition of U6 snRNA Transcription by PTEN. Online J Biol Sci. 2011; 10(3):114-125. PMC: 3071578. DOI: 10.3844/ojbsci.2010.114.125. View

15.

McCluggage W . Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology. 2011; 43(5):420-32. DOI: 10.1097/PAT.0b013e328348a6e7. View

16.

Hu P, Samudre K, Wu S, Sun Y, Hernandez N . CK2 phosphorylation of Bdp1 executes cell cycle-specific RNA polymerase III transcription repression. Mol Cell. 2004; 16(1):81-92. DOI: 10.1016/j.molcel.2004.09.008. View

17.

Cabarcas S, Schramm L . RNA polymerase III transcription in cancer: the BRF2 connection. Mol Cancer. 2011; 10:47. PMC: 3098206. DOI: 10.1186/1476-4598-10-47. View

18.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

19.

Zhong S, Johnson D . The JNKs differentially regulate RNA polymerase III transcription by coordinately modulating the expression of all TFIIIB subunits. Proc Natl Acad Sci U S A. 2009; 106(31):12682-7. PMC: 2722300. DOI: 10.1073/pnas.0904843106. View

20.

Bellido F, Sowada N, Mur P, Lazaro C, Pons T, Valdes-Mas R . Association Between Germline Mutations in BRF1, a Subunit of the RNA Polymerase III Transcription Complex, and Hereditary Colorectal Cancer. Gastroenterology. 2017; 154(1):181-194.e20. DOI: 10.1053/j.gastro.2017.09.005. View